Rising Prevalence and Technological Advancements Drive the Lymphedema Treatment Market

The “Global Lymphedema Treatment Market Size, Share, Growth Analysis, By End-User, By Product, By Condition Type, By Treatment Type – Industry Forecast 2023-2030” report has been added to ResearchAndMarkets.com’s offering.

The global lymphedema treatment market, valued at $786.53 million in 2021, is projected to grow significantly, reaching $1.74 billion by 2030. This robust growth is expected to occur at a Compound Annual Growth Rate (CAGR) of 9.5% during the forecast period of 2023-2030.

Lymphedema: A Growing Health Concern

Lymphedema, characterized by abnormal swelling due to a malfunctioning lymphatic system, primarily affects the lower extremities but can also impact the upper extremities and genitalia. It can result from various factors, including infections like filariasis and as a side effect of breast cancer treatment. Notably, lymphedema is estimated to affect 40% of breast cancer patients.

Market Drivers

Several factors are contributing to the growth of the lymphedema treatment market:

  1. Increasing Prevalence: The rising prevalence of lymphedema and breast cancer cases is a significant driver for the market. The condition can occur at any stage of cancer or following treatment, even years later.
  2. Product Innovation: Major industry players are introducing new products, driving demand for high-quality treatment options, and leveraging technological advancements to develop innovative solutions.
  3. Technological Advancements: Technological developments in lymphedema treatment methods are expected to accelerate market growth. These innovations are improving the effectiveness of treatment and enhancing patient outcomes.
  4. Government Initiatives: Supportive government programs and reimbursement policies are facilitating market growth by reducing the financial burden on patients and healthcare providers.

Challenges

Despite advancements, there is currently no permanent cure for lymphedema, posing a challenge to market growth. Additionally, the rising costs associated with procedures and treatments may limit market expansion.

Market Trends

Key trends driving market growth include the development of innovative and cutting-edge treatments to lower the risks associated with lymphedema. The expansion of the healthcare industry and increased healthcare innovation are also expected to fuel growth.

Segments Covered

The global lymphedema treatment market is segmented based on various factors, including end-user (hospitals, ambulatory surgical centers, specialty clinics, others), product (compression bandages, compression stockings, pneumatic compression devices, others), affected area (genital, lower extremity, upper extremity, others), age group (adult, geriatric), route of administration (oral, injectable, others), type (primary, secondary lymphedema), condition type (cancer, cardiovascular diseases, inflammatory diseases, others), treatment type (compression therapy, surgery, drug therapy, laser therapy, others), and region (North America, Europe, Asia-Pacific, South America, MEA).

Key Players

Leading companies in the global lymphedema treatment market include Bio Compression Systems, Tactile Medical, Medi, Lympha Press, Sigvaris, BSN Medical, L&R USA Inc., Devon Medical Products, 3M Health Care, JOBST USA, Thuasne, Wright Therapy Products, BioHorizons IPH, Inc., Haddenham Healthcare, ArjoHuntleigh, Paul Hartmann, Bioventus, Baxter International Inc., CircAid Medical Products, Inc., Essity Aktiebolag, and others.

For more information about this report visit https://www.researchandmarkets.com/r/wp2yyd

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version